Loading...
Bilateral Trade Intelligence · $1.5K Total Trade · 2 Foreign Suppliers · 3 Indian Buyers · DGFT Verified · Updated March 2026
India imported $1.5K worth of pharmaceutical formulations from Uruguay across 16 verified shipments, from 2 foreign suppliers to 3 Indian buyers. The top suppliers are TECNOBLEN S.A ($1.4K) and MEGA LABS S.A ($20). The leading products are Serum ($1K) and Metformin ($8). Average shipment value: $91.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Serum | $1.4K | 98.6% |
| 2 | Metformin | $8 | 0.6% |
| 3 | Hydrochlorothiazide | $4 | 0.3% |
| 4 | Losartan | $4 | 0.3% |
| 5 | Lansoprazole | $2 | 0.1% |
| 6 | Azithromycin | $1 | 0.1% |
| 7 | Dapagliflozin | $1 | 0.0% |
India imports 7+ pharmaceutical formulations from Uruguay with a combined trade value of $1.5K. Key products include Serum ($1K), Metformin ($8), Hydrochlorothiazide ($4), Losartan ($4), Lansoprazole ($2). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 16 verified Indian Customs (DGFT) shipment records.
2 Indian pharmaceutical companies export finished formulations to Uruguay. Leading exporters include Tecnoblen S.a, Mega Labs S.a, . The top exporter accounts for 98.6% of total India–Uruguay pharma exports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Uruguay and India has experienced modest activity from 2022 to 2026. During this period, India imported pharmaceutical products from Uruguay totaling $1,000 USD across 16 shipments. The average shipment value was approximately $91 USD, indicating a niche but consistent trade relationship. The primary product imported was serum, accounting for 98.6% of the total import value. Other products included metformin, hydrochlorothiazide, losartan, lansoprazole, azithromycin, and dapagliflozin, each contributing smaller percentages to the overall import value.
Uruguay's contribution to India's pharmaceutical imports remains minimal, with a total import value of $1,000 USD over the past four years. This positions Uruguay as a minor supplier in India's diverse pharmaceutical import portfolio. The imports primarily consist of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, with serum being the dominant product.
Between 2024 and 2026, there have been no significant policy changes by the Central Drugs Standard Control Organisation (CDSCO) specifically affecting pharmaceutical imports from Uruguay. Trade agreements or regulatory harmonization efforts during this period have not notably impacted this bilateral trade corridor.
These are the top pharmaceutical products exported from India to Uruguay, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Uruguay buyers, regulatory requirements, and logistics for that specific product corridor. Products include Serum ($1K), Metformin ($8), Hydrochlorothiazide ($4), Losartan ($4), Lansoprazole ($2) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
3 companies in Uruguay import pharmaceutical formulations from India. Top buyers include Himedia Laboratories Private Limited, Azidus Laboratories Limited, Azidus Laboratories Ltd.,, . The largest buyer accounts for 98.6% of India–Uruguay pharma imports. Source: Indian Customs (DGFT).
IMPORT_REGULATORY
Registration process, GMP requirements, import documentation
For Uruguayan pharmaceutical companies to export products to India, they must navigate the CDSCO registration process. This involves appointing an Authorized Indian Representative (AIR) to act as an intermediary between the foreign manufacturer and Indian authorities. The AIR submits the application on behalf of the foreign manufacturer through the CDSCO's SUGAM portal. The application includes Form 40, which details the manufacturing site and the products intended for import. The process requires submission of various documents, such as the Site Master File, Plant Master File, and a Free Sale Certificate. The timeline for approval can vary, but it typically ranges from three to nine months, depending on the product category and completeness of the application.
India mandates that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards to ensure product quality and safety. Manufacturers must provide evidence of GMP compliance, which may include certifications from recognized authorities. The CDSCO may conduct inspections to verify adherence to these standards. Additionally, the manufacturing site must be registered with the CDSCO, a process that involves submitting detailed information about the facility and its operations.
To import pharmaceutical products into India, Uruguayan companies must obtain an import license (Form 10) from the CDSCO. This license authorizes the importation of specific products and is valid for three years. The application for the import license requires submission of a registration certificate, a No Objection Certificate (NOC) from the manufacturer, a test license, and compliance with customs procedures. The test license permits the importation of drugs for testing, analysis, or clinical trial purposes. All documentation must be submitted through the CDSCO's SUGAM portal, and the process involves verification and approval by CDSCO officials.
IMPORT_TRENDS
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical imports from Uruguay to India are predominantly in the form of finished pharmaceutical formulations, with serum being the most significant product. Other imported products include metformin, hydrochlorothiazide, losartan, lansoprazole, azithromycin, and dapagliflozin. These products cater to various therapeutic areas, including cardiovascular diseases, diabetes, and infections. The import of these products suggests a focus on essential medicines that address prevalent health concerns in India.
The imports from Uruguay to India do not prominently feature innovator drugs or novel formulations. The products imported are generally standard formulations that are widely available in the global market. This indicates that the trade is not driven by unique or specialized pharmaceutical innovations from Uruguay.
The demand for pharmaceutical imports from Uruguay to India is likely influenced by factors such as the need for specific formulations not readily available domestically, quality considerations, and cost-effectiveness. The relatively low volume of trade suggests that these factors may not be significant drivers compared to other sources of pharmaceutical imports.
IMPORT_POLICY
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes the Most Favored Nation (MFN) tariff rates, basic customs duty, Integrated Goods and Services Tax (IGST), and health cess. The specific rates can vary based on the product category and are subject to change. Importers must comply with these tariffs and taxes when bringing pharmaceutical products into India.
As of March 2026, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Uruguay that impact pharmaceutical imports. The trade relationship is governed by standard international trade regulations without additional preferential treatment.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and ensures that only genuine innovations receive patent protection. Compulsory licensing provisions allow the government to grant licenses to third parties to produce patented products under certain conditions, such as public health emergencies. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines to ensure affordability. Imported drugs are subject to these price controls, which can affect the pricing strategies of foreign manufacturers.
IMPORT_LOGISTICS
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical products from Uruguay to India are typically transported via sea routes, with major ports in Uruguay such as Montevideo serving as departure points. The transit time for sea shipments can vary but generally ranges from 30 to 45 days, depending on the specific ports of departure and arrival. Air freight is also an option, offering faster delivery times but at a higher cost.
Montevideo is the primary export port in Uruguay for pharmaceutical products. In India, pharmaceutical imports are handled by major ports such as Mumbai, Chennai, and Kolkata. These ports are equipped with facilities to handle pharmaceutical shipments, including temperature-controlled storage for products requiring cold chain logistics.
Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance, which includes verification of documentation and compliance with CDSCO regulations. Products requiring cold chain logistics are stored in temperature-controlled facilities to maintain product integrity. The CDSCO conducts testing and inspections to ensure that imported pharmaceuticals meet the required quality standards. Importers must adhere to Good Distribution Practice (GDP) guidelines to ensure the safe and effective distribution of pharmaceutical products.
IMPORT_OPPORTUNITY
Market size, healthcare system, growth outlook
Despite being a major pharmaceutical manufacturer, India imports certain pharmaceutical products to meet specific domestic needs, address quality requirements, and fill technology gaps. Imports from Uruguay, though minimal, may cater to niche requirements or specific formulations not readily available in India.
Uruguayan pharmaceutical companies exporting to India include TECNOBLEN S.A. and MEGA LABS S.A. These companies supply products such as serum, metformin, hydrochlorothiazide, losartan, lansoprazole, azithromycin, and dapagliflozin to Indian buyers like HIMEDIA LABORATORIES PRIVATE LIMITED and AZIDUS LABORATORIES LIMITED. The trade volume remains low, indicating limited market penetration and the need for strategic partnerships to enhance market presence.
India's Atmanirbhar Bharat initiative and the Production-Linked Incentive (PLI) scheme aim to boost domestic manufacturing and reduce import dependency. While these efforts may lead to increased domestic production of certain pharmaceutical products, the impact on imports from Uruguay is likely to be minimal due to the niche nature of the trade. Imports from Uruguay may continue to serve specific market needs that are not met by domestic production.
IMPORT_COMPETITIVE
Competing origins, India's edge, challenges and threats
India imports pharmaceuticals from various countries, including the USA, EU, China, Switzerland, and Japan. These regions have a more established presence in the Indian pharmaceutical market compared to Uruguay, offering a wider range of products and competitive pricing. Uruguay's share in India's pharmaceutical imports is negligible compared to these major suppliers.
Uruguayan pharmaceutical products may offer advantages such as high-quality manufacturing standards, adherence to international GMP guidelines, and specific formulations that cater to niche market needs. However, the limited volume of trade suggests that these advantages have not significantly influenced Indian buyers' purchasing decisions.
Indian pharmaceutical manufacturers are continually developing alternatives to imported products, including
India exported pharmaceuticals worth $1.5K to Uruguay across 16 verified shipments.
1. TECNOBLEN S.A — $1.4K. 2. MEGA LABS S.A — $20. Total: 2 suppliers.
1. HIMEDIA LABORATORIES PRIVATE LIMITED — $1.4K. 2. AZIDUS LABORATORIES LIMITED — $19. 3. AZIDUS LABORATORIES LTD., — $1. 3 buyers total.
1. Serum ($1.4K, 98.6%); 2. Metformin ($8, 0.6%); 3. Hydrochlorothiazide ($4, 0.3%); 4. Losartan ($4, 0.3%); 5. Lansoprazole ($2, 0.1%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $1.5K corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$91 per consignment across 16 shipments.
2 Indian companies. Largest: TECNOBLEN S.A with $1.4K.
TransData Nexus covers 2 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 16 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Exporters
3 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists